{"disease":{"id":"oral-intraepithelial-neoplasia","name":"oral intraepithelial neoplasia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT02882282","title":"Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}